|
1
|
Ferrando AA, Neuberg DS, Staunton J, Loh
ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland
DG, et al: Gene expression signatures define novel oncogenic
pathways in T cell acute lymphoblastic leukemia. Cancer Cell.
1:75–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg JM, Silverman LB, Levy DE, Dalton
VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE and Asselin BL:
Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber
Cancer Institute acute lymphoblastic leukemia consortium
experience. J Clin Oncol. 21:3616–3622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oudot C, Auclerc MF, Levy V, Porcher R,
Piguet C, Perel Y, Gandemer V, Debre M, Vermylen C, Pautard B, et
al: Prognostic factors for leukemic induction failure in children
with acute lymphoblastic leukemia and outcome after salvage
therapy: The FRALLE 93 study. J Clin Oncol. 26:1496–1503. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seca H, Almeida GM, Guimarães JE and
Vasconcelos MH: miR signatures and the role of miRs in acute
myeloid leukaemia. Eur J Cancer. 46:1520–1527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giza DE and Calin GA: microRNA and chronic
lymphocytic leukemia. Adv Exp Med Biol. 889:23–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yendamuri S and Calin GA: The role of
microRNA in human leukemia: A review. Leukemia. 23:1257–1263. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou X, Xia Y, Li L and Zhang G: MiR-101
inhibits cell growth and tumorigenesis of Helicobacter pylori
related gastric cancer by repression of SOCS2. Cancer Biol Ther.
16:160–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao Y, Gu X, Zhao Y, Greene S, Sha W,
Smoot DT, Califano J, Wu TC and Pang X: Enforced expression of
miR-101 inhibits prostate cancer cell growth by modulating the
COX-2 pathway in vivo. Cancer Prev Res (Phila). 4:1073–1083. 2011.
View Article : Google Scholar
|
|
12
|
Sakurai T, Bilim VN, Ugolkov AV, Yuuki K,
Tsukigi M, Motoyama T and Tomita Y: The enhancer of zeste homolog 2
(EZH2), a potential therapeutic target, is regulated by miR-101 in
renal cancer cells. Biochem Biophys Res Commun. 422:607–614. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo C, Merz PR, Chen Y, Dickes E, Pscherer
A, Schadendorf D and Eichmüller SB: MiR-101 inhibits melanoma cell
invasion and proliferation by targeting MITF and EZH2. Cancer Lett.
341:240–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robertus JL, Kluiver J, Weggemans C, Harms
G, Reijmers RM, Swart Y, Kok K, Rosati S, Schuuring E, van Imhoff
G, et al: MiRNA profiling in B non-Hodgkin lymphoma: A MYC-related
miRNA profile characterizes Burkitt lymphoma. Br J Haematol.
149:896–899. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng J, Guo S, Chen S, Mastriano SJ, Liu
C, D'Alessio AC, Hysolli E, Guo Y, Yao H, Megyola CM, et al: An
extensive network of TET2-targeting MicroRNAs regulates malignant
hematopoiesis. Cell Rep. 5:471–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Papakonstantinou N, Ntoufa S,
Chartomatsidou E, Papadopoulos G, Hatzigeorgiou A, Anagnostopoulos
A, Chlichlia K, Ghia P, Muzio M, Belessi C, et al: Differential
microRNA profiles and their functional implications in different
immunogenetic subsets of chronic lymphocytic leukemia. Mol Med.
19:115–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Correia NC, Melão A, Póvoa V, Sarmento L,
Gómez de Cedrón M, Malumbres M, Enguita FJ and Barata JT: microRNAs
regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
Oncotarget. 7:8268–8281. 2016.PubMed/NCBI
|
|
18
|
Sethi N and Kang Y: Notch signalling in
cancer progression and bone metastasis. Br J Cancer. 105:1805–1810.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roy M, Pear WS and Aster JC: The
multifaceted role of Notch in cancer. Curr Opin Genet Dev.
17:52–59. 2007. View Article : Google Scholar
|
|
20
|
Sahlgren C, Gustafsson MV, Jin S,
Poellinger L and Lendahl U: Notch signaling mediates
hypoxia-induced tumor cell migration and invasion. Proc Natl Acad
Sci USA. 105:6392–6397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu N, Zhang J and Ji C: The emerging
roles of Notch signaling in leukemia and stem cells. Biomark Res.
1:232013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu
X, Sun X, Ma D, Park J, et al: Notch1 is required for
hypoxia-induced proliferation, invasion and chemoresistance of
T-cell acute lymphoblastic leukemia cells. J Hematol Oncol.
6:32013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ninomiya S, Tyybäkinoja A, Borze I, Räty
R, Saarinen-Pihkala UM, Usvasalo A, Elonen E and Knuutila S:
Integrated analysis of gene copy number, copy neutral LOH, and
microRNA profiles in adult acute lymphoblastic leukemia. Cytogenet
Genome Res. 136:246–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fallah P, Amirizadeh N, Poopak B, Toogeh
G, Arefian E, Kohram F, Hosseini Rad SM, Kohram M, Teimori Naghadeh
H and Soleimani M: Expression pattern of key microRNAs in patients
with newly diagnosed chronic myeloid leukemia in chronic phase. Int
J Lab Hematol. 37:560–568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu XY, Liu ZJ, He H, Zhang C and Wang YL:
MicroRNA-101-3p suppresses cell proliferation, invasion and
enhances chemotherapeutic sensitivity in salivary gland adenoid
cystic carcinoma by targeting Pim-1. Am J Cancer Res. 5:3015–3029.
2015.PubMed/NCBI
|
|
27
|
Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ,
Wang XL, Yu F, Liu YL, Yang AG and Gao CF: MiRNA-101 inhibits
breast cancer growth and metastasis by targeting CX chemokine
receptor 7. Oncotarget. 6:30818–30830. 2015.PubMed/NCBI
|
|
28
|
Zheng HB, Zheng XG and Liu BP: miRNA-101
inhibits ovarian cancer cells proliferation and invasion by
down-regulating expression of SOCS-2. Int J Clin Exp Med.
8:20263–20270. 2015.
|
|
29
|
Capaccione KM and Pine SR: The Notch
signaling pathway as a mediator of tumor survival. Carcinogenesis.
34:1420–1430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Neil J, Calvo J, McKenna K,
Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M and Look
AT: Activating Notch1 mutations in mouse models of T-ALL. Blood.
107:781–785. 2006. View Article : Google Scholar
|
|
31
|
Chan SM, Weng AP, Tibshirani R, Aster JC
and Utz PJ: Notch signals positively regulate activity of the mTOR
pathway in T-cell acute lymphoblastic leukemia. Blood. 110:278–286.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Real PJ, Tosello V, Palomero T, Castillo
M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C,
Homminga I, et al: Gamma-secretase inhibitors reverse
glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Nat Med. 15:50–58. 2009. View
Article : Google Scholar
|
|
33
|
Nefedova Y, Cheng P, Alsina M, Dalton WS
and Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow
stromamediated de novo drug resistance of myeloma and other
malignant lymphoid cell lines. Blood. 103:3503–3510. 2004.
View Article : Google Scholar
|
|
34
|
Nefedova Y, Sullivan DM, Bolick SC, Dalton
WS and Gabrilovich DI: Inhibition of Notch signaling induces
apoptosis of myeloma cells and enhances sensitivity to
chemotherapy. Blood. 111:2220–2229. 2008. View Article : Google Scholar
|
